Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | FADS1 | O60427 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 3/20 | 0.37 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5762074 | 1.00 | F10 (0.45) | F10MAOAFADS1F2IKBKE | |
| SCHEMBL3045229 | 0.90 | MAOA (0.51) | F10MAOAFADS1IKBKETBK1 | |
| SCHEMBL6620549 | 0.84 | F10 (0.40) | F10MAOAFADS1F2GRM2 | |
| SCHEMBL6646055 | 0.84 | F10 (0.40) | F10MAOAFADS1F2GRM2 | |
| SCHEMBL6617376 | 0.84 | F10 (0.40) | F10MAOAFADS1F2GRM2 | |
| SCHEMBL5763275 | 0.82 | F10 (0.41) | F10MAOAFADS1F2DGAT1 | |
| SCHEMBL5766169 | 0.82 | F10 (0.41) | F10MAOAFADS1F2DGAT1 | |
| SCHEMBL5763281 | 0.82 | F10 (0.41) | F10MAOAFADS1F2DGAT1 | |
| SCHEMBL6614875 | 0.82 | MAOA (0.44) | F10MAOAF2GRM2MAOB | |
| SCHEMBL3039286 | 0.82 | MAOA (0.44) | F10MAOAF2GRM2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7049443-B2 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | PHARMACIA & UPJOHN COMPANY (US) | 2006-05-23 | — | — | US | disclosed |
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | PHARMACIA & UPJOHN COMPANY | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014967-A1 | Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound | AADAC, AAAS, SLC7A1 | F10 2380/4885MAOA 1179/4885FADS1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.